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Purpose: We evaluated the correlation between the expression of CXCR4 and prog-
nostic factors in patients with prostate cancer.
Materials and Methods: A total of 57 patients who had undergone surgery for prostate 
cancer were enrolled. Specimens were obtained before any treatment and were stained 
with antihuman CXCR4 antibody. The intensity of staining was graded as low or high. 
The age, pretreatment prostate-specific antigen (PSA) level, Gleason score, T stage, 
biochemical recurrence, local recurrence, and distant metastasis were compared ac-
cording to the expression of CXCR4 in patients with prostate cancer.
Results: Local recurrence was higher in the group with high expression, in 11 of 36 cases 
(30.6%), than in the group with low expression, in 1 of 21 cases (4.8%), with statistical 
significance (p=0.040). Distant metastasis was also associated with expression, occur-
ring in 10 of 36 cases (27.8%) in the group with high expression and in 1 of 21 cases 
(4.8%) in the group with low expression (p=0.041). In the logistic regression test, CXCR4 
expression was the only factor in determining local recurrence (p=0.016) and distant 
metastasis (0.022). Furthermore, the group with high CXCR4 expression showed sig-
nificantly longer cancer-specific survival than did the low expression group (p=0.041). 
CXCR4 showed no association with age (p=0.881), pretreatment PSA level (p=0.584), 
Gleason score (p=0.640), T stage (p=0.967), or biochemical recurrence (p=0.081). 
Conclusions: The high expression of CXCR4 was associated with local recurrence and 
distant metastasis. CXCR4 expression was shown to be a useful prognostic factor for 
patients with prostate cancer.
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INTRODUCTION
Prostate cancer is the most commonly diagnosed visceral 
cancer in men and is responsible for the second highest can-
cer-related male mortality rate in Western countries, with 
increasing rates being reported in Korea, Japan, and China 
[1]. Prostate cancer-related deaths are not the result of pri-
mary tumor growth but rather are caused by the spread of 
the cancer to other organs. Cancer metastasis is a sequen-
tial, highly selective process induced by growth factors, cell 
adhesion molecules, and chemoattractants [2]. It has been 
shown that CXCL12-CXCR4 interactions may play a sig-
nificant role in cancer metastasis, and CXCL12 and 
CXCR4 have been implicated in the pathogenesis and pro-
gression of various cancers [3-5].
CXCR4 is one of the chemokine receptors that are being 
actively studied. It plays the role of a co-receptor of HIV en-
try and also a role in controlling metastasis in various tu-
mors such as prostatic cancer. A large amount of CXCL12 
is formed in organs where tumor metastasis frequently oc-
curs, such as liver, lung, and bones [6]. The tumor cells that 
manifest CXCR4, which is a receptor of the same family as 
CXCL12, move to these organs to combine with CXCL12, 
causing cancer metastasis. Korean J Urol 2011;52:607-611
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FIG. 1. CXCR4 expression in prostate cancer tissue (anti-CXCR4 antibody, x200). (A) Low expression, (B) High expression.
Studies of the correlation of the CXCL12-CXCR4 li-
gand-receptor system with the pathology and prognosis of 
various tumors are currently being conducted. For exam-
ple, correlations of the manifestation of CXCR4 with lung 
cancer, melanoma, esophageal cancer, and ovarian cancer 
have been reported [7-10]. Furthermore, it was reported 
that the manifestation of CXCR4 in prostatic cancer was 
associated with low cancer-specific survival [11], and that 
the CXCL12-CXCR4 interaction played an important role 
in the bone metastasis of prostatic cancer [3]. 
To investigate the effect of the manifestation of CXCR4 
on prostatic cancer, we examined the relationship between 
CXCR4 and the prognostic factors of prostatic cancer. 
MATERIALS AND METHODS
1. Subjects
The subjects of this study were 57 patients with a diagnosis 
of prostate cancer who underwent retropubic radical pros-
tatectomy between January 2001 and February 2008. The 
age of the patients, pretreatment prostate-specific antigen 
(PSA) level, Gleason score, T stage, biochemical re-
currence, local recurrence, and distant metastasis during 
the follow-up period were examined, and the average fol-
low-up period was 39 months (range, 12 to112 months). 
One pathologist evaluated the stage of the primary tumor 
and the Gleason score of the tumors by observing samples 
stained with H&E under an optical microscope. Biochemi-
cal recurrence was defined as an increase in PSA above 0.2 
ng/ml, twice or more in succession, during the follow-up 
period.
2. Immunohistochemical staining
A pathologist reexamined the H&E stained sample of the 
target case and marked the representative tumor site. A 
core with a 3 mm diameter was collected from the corre-
sponding paraffin block and a tissue microarray (TMA) was 
produced. The TMA paraffin block was cut into a slice with 
a thickness of 4 μm and attached to a slide. It was deparaffi-
nized for 5 minutes in Xylene three times and passed 
through an anhydrous process before being washed with 
distilled water. The TE buffer solution (pH 9.0) was used 
as a pretreatment for restoration of antigenicity. The sam-
ple was stained with the Autostainer 360 (Lab Vision, 
Fremont, CA, USA) using UltraVision LP Detection 
(Thermo Scientific, Waltham, MA, USA). For the primary 
antibody response, CXCR4 (sc-6191, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) was diluted at 1:100 and re-
acted for 40 minutes at room temperature. For contrast 
stain, Mayer's hematoxylin was used.
3. Evaluation of immunohistochemical staining
Two pathologists each interpreted the staining without 
prior knowledge of any of the clinicopathologic parameters. 
If the pathologists’ analysis did not correspond, the stain-
ing was interpreted again. A judgement was made as to the 
proper immunohistochemical score of the tumors on the ba-
sis of the intensity of CXCR4 expression as follows: neg-
ative, weak, moderate, and strong staining. Samples with 
immunohistochemical scores of negative or weak were con-
sidered to have low expression and those with moderate to 
strong distributions were considered to have high ex-
pression of CXCR4 antibodies (Fig. 1).
4. Statistical analysis
The Gleason score (6 or lower, 7 or higher), pretreatment 
PSA level, T stage, biochemical recurrence, local re-
currence, distant metastasis during the follow-up period, Korean J Urol 2011;52:607-611
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TABLE 1. Clinicopathological characteristics of the patients 
Variables
Mean age (yr)
Mean pretreatment PSA (ng/ml)
Gleason score
    ≤6
    ≥7
T stage
    T2
    T3
    T4
Biochemical recurrence
    No
    Yes
Local recurrence
    No
    Yes
Distant metastasis
    No
    Yes
Positive surgical margin 
  64 (51-76)
     7.6 (3.2-18.4)
No. of patients (%)
24 (42.1)
33 (57.9)
49 (86.0)
  8 (14.0)
0 (0)
38 (66.7)
19 (33.3)
45 (78.9)
12 (21.1)
46 (80.7)
11 (19.3)
  8 (14.0)
PSA: prostate-specific antigen 
TABLE 2. Comparison of clinicopathological characteristics 
according to CXCR4 expression
Variables
CXCR4 expression
p-value Low
(n=21)
High
(n=36)
Age (yr)
Mean pretreatment PSA 
  (ng/ml)
Gleason score
    ≤6 (%)
    ≥7 (%)
T stage
    T2 (%)
    T3 (%)
Biochemical recurrence
    No (%)
    Yes (%)
Local recurrence
    No (%)
    Yes (%)
Distant metastasis
    No (%)
    Yes (%)
65.1±11.5
7.2±4.2
    8 (38.1)
  13 (61.9)
  18 (85.7)
    3 (14.3)
  17 (81.0)
    4 (19.0)
  20 (95.2)
  1 (4.8)
  20 (95.2)
  1 (4.8)
63.5±10.7
8.5±3.9
16 (44.4)
20 (55.6)
31 (86.1)
  5 (13.9)
21 (58.3)
15 (41.7)
25 (69.4)
11 (30.6)
26 (72.2)
10 (27.8)
0.881
a
0.584
a
0.640
b
0.967
c
0.081
b
0.040
c
0.041
c
PSA: prostate-specific antigen, 
a: student’s t-test, 
b: Pearson 
chi-square test, 
c: Fisher’s exact test
and cancer-specific survival were compared according to 
the expression of CXCR4 in prostate cancer. Statistical sig-
nificance was analyzed by using the Student’s t-test, 
chi-square test, and logistic regression analysis with SPSS 
ver. 12.0 (SPSS Inc., Chicago, IL, USA). Cancer-specific 
survival was calculated by the Kaplan-Meier method. 
Statistical significance was based on a p-value less than 
0.05.
RESULTS 
1. Clinicopathologic characteristics
The mean age of the patients was 64 years (range, 51 to76 
years) and their mean pretreatment PSA level was 7.6 
mg/ml (range, 3.2 to 18.4 ng/ml) (Table 1). Twenty-four pa-
tients had a Gleason score of 6 or lower (42.1%) and 33 cases 
had a score of 7 or higher (57.9%). T stages were as follows: 
T2 in 49 cases (86.0%), T3 in 8 cases (14.0%), and T4 in 0 
cases. Biochemical recurrence was detected in 19 cases 
(33.3%), local recurrence in 12 cases (21.1%), and distant 
metastasis in 11 cases (19.3%). Positive surgical margins 
were detected 8 cases (14.0%; low; 3; high, 5), and there was 
no significant difference between the 2 groups (p=0.215).
2. Expression profiles of CXCR4
CXCR4 was detected in 93.0% of the patients (53/57) with 
prostate cancer specimens (Table 2). Among all patients, 
the group with low CXCR4 expression contained 21 pa-
tients (36.8%; negative, 4; weak, 17), and the group with 
high expression contained 36 patients (63.2%; moderate, 
30; strong, 6). 
Local recurrence of prostate cancer was higher in the 
group with high expression (30.6%, 11/36) than in the group 
with low expression (4.8%, 1/21; p=0.040). Distant meta-
stasis was also associated with expression: it occurred in 
27.8% (10/36) of the group with high expression and 4.8% 
(1/21) of the group with low expression (p=0.041). In the lo-
gistic regression analysis, CXCR4 expression was the only 
factor affecting local recurrence (p=0.016) and distant 
metastasis (p=0.022) among age, pretreatment PSA, 
Gleason score, and CXCR4. Furthermore, the high CXCR4 
expression group showed significantly longer cancer-spe-
cific survival than did the low expression group (p=0.041) 
(Fig. 2).
CXCR4 showed no association with age (p=0.881), pre-
treatment PSA level (p=0.584), Gleason score (p=0.640), T 
stage (p=0.967), or biochemical recurrence (p=0.081). 
DISCUSSION
The soluble attractant molecule, chemokine, was found to 
play a role in metastasizing specific tumors to other organs 
[6]. This chemokine is composed of small, basic chemotactic 
proteins that play a role in its function by combining with 
G-protein-coupled receptor (chemokine receptor) [12]. 
This was found to play a role in the direct extravasation in 
inflammatory cells [13]. Just as leukocytes gather to in-
flammatory cells, tumor cells move because these chemo-
kines want to combine with chemokine receptors [14-16].
There have been many studies on the role of the 
CXCL12-CXCR4 ligand-receptor system in immunology 
and infection areas such as hematopoiesis, lymphocyte 
homing, and HIV infection. In 2001, Müller et al demon-Korean J Urol 2011;52:607-611
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FIG. 2. Kaplan-Meier univariate survival analysis in patients 
with prostate cancer according to CXCR4 expression.
strated that CXCR4 manifested much more in breast can-
cer tissues than in normal breast tissues [6]. They also 
showed that CXCL12 manifested in organs in which breast 
cancer metastasis frequently occurs, such as lymph nodes, 
bone marrow, and lung, but did not manifest in kidney, 
where metastasis seldom occurs. Moreover, an in vivo 
study found that injecting antibodies neutralizing the 
CXCR4 activity decreased metastasis [6]. These reports 
suggest that the CXCL12-CXCR4 ligand-receptor system 
plays an important role in determining the metastatic des-
tination of cancer cells. Similar results were reported for 
tumors such as esophageal tumors, malignant melanoma, 
ovarian cancer, and lung cancer [9,17-19]. However, such 
studies have not yet been actively conducted for prostate 
cancer.
In a previous study on prostate cancer and CXCR4, 
Mochizuki et al reported that positive CXCR4 protein was 
found in 57.1% of prostatic samples and stated that the 
CXCR4 manifestation is an independent predictor of bone 
metastasis and was better for prediction of bone metastasis 
than was the Gleason score [20]. A study on metastatic 
prostate cancer found that the high CXCR4 manifestation 
group showed poorer cancer-specific survival compared 
with the low CXCR4 manifestation group [11]. Our study 
investigated the correlations of CXCR4 manifestation with 
clinicopathological factors, recurrence, and metastasis 
and found that CXCR4 manifestation was related to local 
recurrence and distant metastasis. We confirmed that 
CXCR4 was the only factor affecting local recurrence and 
distant metastasis, and the high CXCR4 expression group 
showed longer cancer-specific survival than did the low ex-
pression group. These results support the fact that CXCR4 
is a useful prognostic factor in prostate cancer, and the 
CXCL12-CXCR4 ligand-receptor system plays an im-
portant role in the metastasis of prostate cancer to other 
organs.  In all studies, however, CXCR4 had no correlation 
with the important predictors of the recurrence of prostatic 
cancer, such as pretreatment PSA level, clinical stage, and 
Gleason score. The reason for this may be the existence of 
detection bias because immunohistochemical staining was 
performed for only a part of prostate cancer specimens. 
More studies with a larger number of cases are needed to 
confirm the significance of CXCR4 in prostate cancer.
The fact that CXCR4 is a significant prognostic factor in 
prostate cancer patients and that the manifestation of 
CXCR4 indicates poor prognosis suggest that inhibiting 
CXCR4 could be a possible therapeutic target. In fact, in 
vitro, anti-CXCR4 antibodies used in therapeutic strat-
egies in a prostate cancer cell line are largely classified into 
two categories: antibody for CXCR4 and specific CXCR4 
antagonist. It was first reported that in the severe com-
bined immunodeficiency (SCID) mouse model, the in-
jection of the antihuman CXCR4 monoclonal antibody re-
stricted the lung metastasis of human breast cancer [6]. 
This antibody was also found to restrict lung metastasis in 
murine B16 melanoma and bone metastasis of human 
prostate cancer in the murine model [19,21]. Recently, 
however, the CXCR4 antagonist was suggested to be a 
promising therapy for cancer metastasis. AMD3100 is the 
most powerful and selective CXCR4 antagonist that has 
been discovered to date [22]. AMD3100 effectively re-
stricted the growth of brain tumor (glioblastoma cell) that 
had been injected into mice and also increased the apopto-
sis of cells [23]. T140, another CXCR4 antagonist, was 
found to decrease pulmonary metastasis of human breast 
cancer cells in SCID mice [24]. Both AMD3100- and 
T140-derived CXCR4 antagonists were found to be active 
in the animal tumor model, providing the basis for later 
clinical experiments using this drug in many tumor pa-
tients [25,26]. 
Efforts at understanding the role of CXCR4 in cancer bi-
ology and finding treatment methods by inhibiting the 
CXCR4 mechanism may provide novel treatment 
approaches.
CONCLUSIONS
The high expression of CXCR4 was associated with local 
recurrence and distant metastasis. According to our study, 
CXCR4 expression is a useful prognostic factor for patients 
with prostate cancer. More studies with a larger number 
of cases are needed to confirm the clinical significance of 
CXCR4 in prostate cancer.
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